Partnerships are a key cornerstone to LCT’s success over the years. We are always interested in expanding our relationships that can accelerate the development of our products and research programs, and expand our global reach.
LCT has partnered with Otsuka Pharmaceutical Factory, Inc. (OPF) to form a 50/50 company Diatranz Otsuka Limited (DOL). LCT has sold its DIABECELL® to DOL for $A25 and OPF has injected $A25m cash for their 50% interest. This partnership will accelerate the commercialisation of DIABECELL.
We are also interested in research collaborations with our NTCELL, a choroid plexus cell product that delivers beneficial proteins and neurotrophic factors to the brain to treat neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, stroke and hearing loss.
Our breakthrough encapsulation delivery technology, IMMUPELTM, is available for license. We will process your live cells in our GMP facility for your research program, enabling your therapy to be delivered without immunosuppression.
LCT also has biocertified porcine tissue available for medical use, and we are actively seeking partners interested in these biomaterials.
LCT has the world’s only internationally accredited xenodiagnostic laboratory, and is available for molecular diagnostic testing.
For additional information on any of these partnering opportunities,please contact us at firstname.lastname@example.org